Please join Parent Project Muscular Dystrophy and Catabasis Pharmaceuticals as we host a webinar Wednesday, October 11 at 1:00 PM EDT to hear a community update on the results from the open-label extension of the MoveDMD trial following 24 and 36 weeks of edasalonexent treatment in boys with Duchenne muscular dystrophy.
- Pat Furlong
Founding President & CEO, Parent Project Muscular Dystrophy
- Joanne M. Donovan, M.D., Ph.D.
Chief Medical Officer, Catabasis Pharmaceuticals
Dr. Joanne Donovan is the Chief Medical Officer of Catabasis Pharmaceuticals, Inc. She received her academic training at MIT, Harvard and Brigham & Women’s Hospital and has more than 15 years of experience in drug development taking programs from Phase 1 to approval. Dr. Donovan is currently Associate Clinical Professor of Medicine at Harvard and continues to practice and teach medicine.
View call-in information & pre-register to receive a reminder email for this webinar.
Please submit questions in advance to firstname.lastname@example.org (subject line: Catabasis Webinar) by Monday, October 9th at 12:00 PM ET.